A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months

Inclusion Criteria: * MS patients diagnosed with clinically definite MS according to the McDonald criteria (Polman et al., 2005) * Being on GA monotherapy (20mg/day sc) for at least 24 months prior to the 24-month MRI scan * Having baseline clinical MRI scan that included SWI-filtered phase imaging in a 12-month window from the start day of the of the GA (MS patients) * Having baseline clinical MRI scan that included SWI-filtered phase imaging (healthy controls) * MS patients having a RR disease course (Lublin and Reingold, 1996) * Age 18-65 (healthy controls will be matched to MS patients for age and sex) * Signed informed consent at the 24-month follow-up * Pass MRI health screening * MS patients passing contrast screening * MS patients having normal kidney function (creatinine clearance \>59) * None of the exclusion criteria Exclusion Criteria: * Patients who had a relapse within 30 days prior to MRI baseline scan date * Patients who received steroid treatment within 30 days prior to the MRI baseline scan date * Women who are pregnant, lactating or of childbearing age who do not consent to approved contraceptive use during the study * MS patients who used other imunomodulatory or immunosuppressant treatment other than GA during the follow-up (e.g., IFN-β, mitoxantrone, cyclophosphamide, cladribine, fludarabine, cyclosporine, total body, azathioprine, methotrexate, IVIG, cellcept, natalizumab, etc.) * MS patients having abnormal kidney function (creatinine clearance \<59)